Furthermore, randomized clinical trials demonstrated an OS benefit of docetaxel in males with metastatic castrate-sensitive and -resistant PC.11,12,13 However, the addition of docetaxel to RT and ADT in males with nonmetastatic unfavorable-risk PC had negative or inconclusive results.14,15,16,17 Thus, there is a need for further study to identify the subgroup of unfavorable-risk PC patients who would benefit from the treatment intensification with AR-signaling inhibitors or cytotoxic chemotherapy. This evidence concerns the gene AR and pachyonychia congenita.